The IMCA-CAT insertion device synchrotron beamline is designed with state-of-the-art equipment and is ideally suited for proprietary drug discovery research.
Intense focused beam, robotics for sample mounting, diffraction rastering and high-speed precision sample positioning, and shutterless continuous-rotation data collection enable the beamline to meet the throughput demands of the pharmaceutical industry.
Some highlights of the beamline capabilities include tunability for MAD and SAD experiments, selectable mini beam for optimum beam size, and collect-along-a-vector for overcoming sample degradation.
High-throughput data acquisition at IMCA-CAT accelerates both the discovery and the lead optimization phases of drug development.
The beamline experiment end station is designed with equipment that enables structural studies of the most challenging complexes.
Automated data collection and processing meet the throughput demands of fragment screening.
High-speed, secure, and encrypted data transfer enable on-the-fly structural analyses.
More than 15,000 structures are solved annually from data collected at the IMCA-CAT synchrotron beamline.
Access for proprietary data acquisition, whether on-site, remotely, or via mail-in, is guaranteed and frequent, thereby integrating smoothly with pharmaceutical drug design work flows.
The IMCA-CAT research facility, aimed at accelerating pharmaceutical drug discovery programs, performs to the highest standards of reliability, efficiency, and throughput.